KPI-190 is a part of the ShK family and is being developed as an eye drop for use in several eye diseases including uveitis and Dry Eye Syndrome (DES).
Pathogenic T cells have been shown to play a role in autoimmune eye disease as T cell infiltration and cytokine and chemokine production lead to tissue damage in the eye. Kv1.3-HIGH autoreactive TEM cells have been identified in uveitis and DES making these conditions a good option for development of KPI-190.
Uveitis is one of the leading causes of blindness in the US and remains a significant unmet need. There are over 680,000 uveitis patients in the US with very few treatment options. Dry eye syndrome affects over 13 million people a year in the US alone and current treatments are either ineffective at treating the underlying disease or are toxic if used over long periods of time.
KPI-190 has demonstrated proof of concept efficacy in models of anterior uveitis, and topically administered it has good penetration into the anterior chamber.